Final overall survival in JO22903, a phase II, open-label study of first-line erlotinib for Japanese patients with EGFR mutation-positive non-small-cell lung cancer

BACKGROUND: In Japan, the clinical efficacy of erlotinib monotherapy in epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer was demonstrated in the phase II JO22903 trial, which reported a median progression-free survival of 11.8 months. Here we report final overall...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Int J Clin Oncol
Main Authors: Yamamoto, Noboru, Goto, Koichi, Nishio, Makoto, Chikamori, Kenichi, Hida, Toyoaki, Maemondo, Makoto, Katakami, Nobuyuki, Kozuki, Toshiyuki, Yoshioka, Hiroshige, Seto, Takashi, Tajima, Kosei, Tamura, Tomohide
Format: Artigo
Jezik:Inglês
Izdano: Springer Japan 2016
Teme:
Original Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5306267/
https://ncbi.nlm.nih.gov/pubmed/27659294
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10147-016-1039-0
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki